Company intelligence / Profile preview
Gyala Therapeutics
Barcelona, Catalonia, Spaingyalatx.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Gyala Therapeutics is developing CAR-T cell therapies targeting CD84 and dual CD19/CD84 for hematological malignancies, particularly acute myeloid leukemia, with all programs currently in preclinical development[2][4].
- Therapeutic areas
- HematologyOncology
- Modalities
- CAR-T cell therapySmall molecule
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
University of Salerno (for Compound 3)[4]Hospital Clínic de Barcelona – IDIBAPS (founding and collaboration partner)[1][2]
Beyond the preview
Go deeper on Gyala Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gyala Therapeutics.